Background. The benefit of neoadjuvant chemotherapy (NAC) in patients with estrogen receptor-positive (ER?)/ human epidermal growth factor receptor 2-negative (HER2-) breast cancers and in invasive lobular carcinoma (ILC) is uncertain due to the low rates of pathologic complete response (pCR). Objective. The aim of this study was to determine if pathologic features can identify subsets likely to benefit from NAC. Methods. Patients with stage I-III ER?, HER2-breast cancer receiving NAC were retrospectively reviewed. Endpoints were downstaging to breast-conserving surgery (BCS) and nodal pCR after NAC. Patients were grouped by progesterone receptor (PR) status and grade/differentiation (high grade or poor [HP] vs. non-HP). Results. From 2007 to 2016, 402 ER?/HER2-cancers in patients receiving NAC were identified. Median age was 50 years, 98% were clinical stage II-III, and 75% were cN?. Overall pCR rate was 5%; breast pCR in 7% and nodal pCR in 15% of cN? patients (p \ 0.0001). Patients with ILC initially ineligible for BCS (n = 56) were less likely to downstage than those with invasive ductal carcinoma (IDC; n = 183, 16 vs. 48%, p B 0.0001), with a similar trend in the axilla (p = 0.086). The rates of BCS eligibility after NAC were highest in PR-/HP patients (62%) and lowest in PR?/non-HP patients (29%) [p = 0.005]. In the axilla, nodal pCR among cN? patients (n = 301) ranged from 0 to 35% (p \ 0.0001) within these groups, and was most frequent in PR-/HP patients. Conclusions. ER?/HER2-patients most likely to benefit from NAC are those with PR-and HP tumors. Patients with ILC are unlikely to downstage in the breast or axilla compared with IDC. The use of these criteria can assist in defining the initial treatment approach.
Neoadjuvant chemotherapy (NAC) in patients with operable breast cancer offers several potential benefits, including downstaging the primary tumor to allow breast conservation, 1,2 as well as eradicating axillary nodal disease with a reduction in the need for axillary dissection. [1] [2] [3] Rates of pathologic complete response (pCR) to NAC vary widely by breast cancer subtype, and are consistently lower in hormone receptor-positive (HR?)/human epidermal growth factor receptor 2-negative (HER2-) breast cancers (ranging from 2 to 11%) than in triple-negative and HER2? breast cancer, where pCR rates range from 18 to 45%. [4] [5] [6] [7] [8] [9] Although pCR rates are lowest in HR?/HER2-disease, patients with this subtype have a high partial response rate to NAC, 4 which may allow breast-conserving surgery (BCS) in patients initially requiring mastectomy; however, there are inconsistent data regarding the rates of BCS after NAC for HR?/HER2-patients compared with other subtypes. 4, 9 Patients with invasive lobular carcinoma (ILC), which is classically estrogen receptor-positive (ER?), low grade, and well-differentiated, have also been shown to have a poor response to NAC, with significantly lower rates of pCR than seen in patients with infiltrating ductal cancer. [10] [11] [12] The lower rates of pCR translate into lower rates of BCS after NAC than seen with invasive ductal carcinoma (IDC), [9] [10] [11] [12] but whether these differences are the result of histology per se or other features, such as grade and receptor status, has been questioned. 13, 14 The issue of selection of patients likely to benefit from NAC has achieved new importance with the demonstration in prospective trials [15] [16] [17] that patients presenting with axillary nodal metastases can be accurately staged with sentinel lymph node biopsy after NAC, allowing the avoidance of axillary dissection in those who achieve nodal pCR. Additionally, rates of pCR in the axillary nodes have been shown to be higher than in the breast in HR?/HER2-patients, 4, 18 providing further impetus for the use of NAC in this subgroup of patients. The purpose of this study was to compare rates of breast and nodal pCR in patients with infiltrating ductal and infiltrating lobular carcinoma, and to examine the impact of routinely reported pathologic features on the rate of pCR in HR?/HER2-and downstaging to BCS in patients receiving NAC.
METHODS

Study Population
This was an Institutional Review Board-approved, Health Insurance Portability and Accountability Act (HIPAA)-compliant study. A retrospective review of the Memorial Sloan Kettering Cancer Center database was conducted to identify all patients with stage I-III breast cancer treated with NAC between 2007 and 2016. Patients were eligible for inclusion if they were ER? and/or progesterone receptor-positive (PR?) and HER2-based on their pretreatment core biopsy. Hormone receptor positivity was defined as C10% of cells staining positive for ER or PR. This definition was chosen since there is little debate on the use of NAC in patients with lower levels of hormone receptor expression. HER2 receptor was defined as negative with immunohistochemical staining of 0 or 1?, or fluorescent in situ hybridization that was not amplified. Patients were excluded if they had an excisional biopsy for diagnosis, or if any portion of their surgery, including sentinel lymph node biopsy, was completed prior to receipt of NAC. Patients previously treated with BCS with an ipsilateral breast cancer recurrence were also excluded.
The primary endpoints of the study were breast tumor downstaging to allow BCS in patients initially requiring mastectomy, and nodal pCR. Upfront and post-NAC eligibility for BCS was recorded prospectively by the treating breast surgeon. Patients eligible for BCS at presentation, or those requiring mastectomy due to contraindications to BCS, such as inflammatory breast cancer or multicentric disease, were excluded from the breast endpoint calculation, while patients who were clinically node negative (cN0) at presentation were excluded from the nodal pCR endpoint calculation. pCR in this study was defined as the absence of invasive and in situ disease in the breast and nodes.
Clinicopathologic Features
Patients were considered clinically node positive (cN?) if they had suspicious palpable lymph nodes at presentation or if carcinoma was identified in the lymph nodes by needle biopsy. Pathologic features collected from the initial core biopsy pathology reports included ER and PR expression, nuclear grade, differentiation using the Scarff-BloomRichardson classification, 19 and histology. Patients with mixed ductal and lobular histology were classified as having lobular histology. Classic lobular carcinomas were classified as grade 1 and well-differentiated when not otherwise specified in the pathology report.
The associations between each of the pathologic features, and downstaging to eligibility for BCS or nodal pCR, were assessed using the Chi-square test and multivariate logistic regression analysis. A subsequent analysis was based on grouping of PR status and grade/differentiation, with PR? versus PR-grouped with high-grade or poor differentiation versus non-high-grade and non-poor differentiation. These associations were tested using the Chisquare test. The four ER-/PR? patients were excluded. All analyses were conducted using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA). A p-value \0.05 was considered statistically significant.
RESULTS
From 2007 to 2016, a total of 391 patients (11 with bilateral cancer) receiving NAC for HR?/HER2-cancers were identified, yielding a sample of 402 cancers. Clinicopathologic characteristics of the study population are listed in Table 1 . Median patient age was 50 years (range 27-79), and median clinical tumor size was 5.0 cm. Sixtyeight percent of patients had clinical T2 and T3 tumors, and 301 (75%) were cN? at presentation. Of the cN? patients, 45 (15%) had suspicious palpable nodal disease and 256 (85%) had biopsy-confirmed nodal involvement. Overall, 310 (77%) cancers were ductal and 91 (23%) were pure or mixed lobular cancers. The clinicopathologic characteristics of the ductal and lobular groups are compared in Table 1 . Ductal cancers were more commonly high grade or poorly differentiated than lobular cancers. Doxorubicin, cyclophospahamide, and a taxane was the most common type of chemotherapy, received in 390 (97%) cases.
The overall pCR rate was 5% (n = 21). Breast pCR was seen in 7% (n = 27) of the 402 cancers and nodal pCR was seen in 15% (n = 45) of the 301 cN? patients (p \ 0.001). Overall pCR was more common in ductal than lobular cancers, with 6% (n = 19) of ductal carcinomas and 1% (n = 1) of lobular carcinomas having pCR (p = 0.055). One occult cancer presenting with nodal metastases with unknown histology had a pCR.
Two hundred and thirty-nine of the 402 cancers were potentially eligible for downstaging to BCS with NAC ( Fig. 1) , and 109 were felt to be candidates for BCS posttreatment. Twelve of these patients ultimately required mastectomy, resulting in 97 (41%) patients who had BCS, or were eligible to do so but opted for mastectomy. These 97 patients were considered successfully downstaged for BCS after NAC.
Multiple clinicopathologic features were associated with downstaging to BCS and nodal pCR in univariate analysis (Table 2) . A significantly higher rate of downstaging to BCS was seen in patients with IDC compared with ILC (48 vs. 16%; p \ 0.0001). Axillary pCR was also more frequent among ductal carcinomas, but this difference did not reach statistical significance (16 vs. 7%; p = 0.086). Poorly differentiated tumors and those lacking PR expression were significantly associated with downstaging to BCS, while grade, differentiation, and lack of PR expression were all significantly associated with nodal pCR. In a multivariate model (Table 3) including differentiation, PR status, and histology, which was limited to patients with complete data, histology was significantly associated with downstaging to BCS. Patients with lobular carcinomas were 78% less likely to downstage (odds ratio [OR] 0.22; p = 0.0007) than those with ductal carcinoma. The only factor that remained significantly associated with nodal pCR was poor differentiation (OR 2.667; p = 0.014).
We also performed an analysis examining factors that were significant on univariate analysis, including grade, differentiation, and PR expression, to increase the utility of the model in patients with infiltrating ductal carcinoma. The combination of PR status and grade or differentiation Table 4 ]. The greatest likelihood of downstaging in the breast was seen in the PR-/high-grade or poorly differentiated tumors (62%) compared with 29% in the PR?/non-high-grade, non-poorly differentiated tumors. The PR-/high-grade or poorly differentiated group also had the highest rate of nodal pCR (35%). Each of the other groups had a \15% rate of nodal pCR.
DISCUSSION
The low rate of pCR in patients with ER?/HER2-breast cancers has raised questions regarding the utility of NAC in this subtype. In patients with ER?/HER2-cancers, pCR is not associated with a survival benefit as is seen in other subtypes, 20 but achieving a pCR is not the only goal of treatment with NAC. Other benefits include increasing eligibility for BCS and decreasing the rate of axillary nodal metastases. In this study, we found that 41% of patients who were not candidates for BCS at presentation were eligible for BCS after NAC. The low pCR rate in patients with ER?/HER2-cancers has not consistently translated to lower rates of BCS after NAC compared with patients with other subtypes. Boughey et al. conducted a retrospective analysis of patients enrolled in the American College of Surgeons Oncology Group (ACOSOG) Z1071 trial assessing rates of pCR and BCS based on ER, PR, and HER2 status, and found a significantly lower rate of BCS in HR?/HER2-patients compared with other subtypes (p = 0.019). 4 In contrast, Straver et al. conducted a similar study restricted to the cohort of patients initially requiring mastectomy and found no significant difference in rates of BCS when comparing subtypes (p = 0.11). 9 The majority of studies assessing BCS rates after NAC have compared the rate of BCS as the final surgical procedure, regardless of patient eligibility for BCS at presentation. 4, [10] [11] [12] We were able to identify whether patients required a mastectomy or were candidates for BCS While we found a low rate of pCR in the breast of 7% of patients, the use of histologic tumor type, PR expression, and differentiation or nuclear grade identified subsets of patients significantly more likely to respond to NAC, with 22 and found that PR-tumors had a 35% rate of breast-only pCR and near pCR, significantly higher than the 12% seen in PR? tumors (p \ 0.001). The group's neoadjuvant response index (NRI), calculated from breast and axillary response scores, was found to be significantly higher for PR-and luminal B tumors. In the combined PR?/luminal A group, 50% of patients had an NRI below the median, compared with only 25% of the PR-/luminal B group. However, they concluded that because excellent responses occurred in both groups, they could not identify a chemoresistant subgroup.
Our findings support these results; we saw higher chemosensitivity in PR-and high-grade or poorly differentiated tumors. Our results also confirm that the subset of patients who are both PR-and high grade or poorly differentiated are the most likely to have primary tumor downstaging as well as axillary pCR. Although Lips et al. showed similar results, 22 the clinical applicability of their NRI score is unknown. We were able to corroborate their results using clinically relevant endpoints. Other investigators have found Ki-67 measurement, either initially or after a short course of endocrine therapy, to be a predictor of response to NAC in ER?/HER2-patients. 23, 24 Measurement of Ki-67 is not a part of routine pathologic evaluation at Memorial Hospital, therefore we were unable to evaluate whether Ki-67 results would further refine the identification of a subset of patients most likely to benefit from NAC.
While there are many factors, in addition to response to NAC, that determine patient suitability for BCS after NAC, 25 only patients who obtain a nodal pCR are able to avoid axillary dissection. The rate of nodal pCR in our study was 15% among women who initially presented with cN? disease. When PR expression and grade or differentiation were included in the analysis, we found a 35% rate of nodal pCR in patients with tumors that both lack PR expression and are high grade or poorly differentiated, with a nodal pCR of \15% in each of the other subsets of patients. We observed that nodal pCR was more frequent than breast pCR, even when breast pCR was defined as the absence of invasive carcinoma alone. This is similar to a previous observation from our institution in a smaller cohort of HR?/HER2-patients, 18 where Mamtani et al. observed a nodal pCR rate of 21% for ER?/HER2-patients compared with a breast pCR rate of 5% (p = 0.03). This finding suggests a clear role for NAC in ER? HER2-patients presenting with nodal metastases.
We also attempted to determine if patients with lobular histology obtain any significant benefit from NAC, and found that 16% of lobular carcinomas downstaged to become eligible for BCS after NAC, a significantly lower rate than the 48% of ductal carcinomas that downstaged. We saw similar trends when comparing overall pCR and nodal pCR rates for ILC versus IDC. In our study, patients with ILC had a 7% rate of nodal pCR, which was less than half that seen in IDC, and only a 1% overall pCR rate versus 6% in IDC. Delpech et al. retrospectively evaluated the pCR rates and BCS rates after NAC in ER? ductal versus lobular carcinomas. 13 They found that BCS was significantly less frequent in ILC than IDC patients (19 vs. 34%; p \ 0.001) and histology remained a predictor of mastectomy after adjusting for age, tumor grade, size, multifocality, stage, and nodal status. Lips et al. also evaluated the response to NAC in ILC versus IDC and stratified by subtype.
14 When adjusted for HR and HER2 status, lobular histology was not associated with a lower pCR rate than ductal, with HR?/HER2-tumors having a 7 versus 5% pCR rate, respectively (p = 0.76). They also found that BCS rates did not significantly differ when evaluated within T stage.
One of the limitations of our study was that several patients were missing data, mainly for nuclear grade or differentiation. Because multivariate analyses were restricted to patients with complete data, they had limited power, limiting the conclusions that can be drawn from their results. However, even with smaller numbers, histology and differentiation were significant predictors of tumor downstaging and nodal PCR, respectively. An important caveat is that patients in our cohort were selected for NAC based on clinicopathologic features or locally advanced disease, and the results observed may not be applicable to all HR?/HER2-breast cancer patients.
CONCLUSIONS
Clinically meaningful variation in response to NAC is seen based on features routinely available in core biopsy pathology reports. Knowledge of these response rates in subsets of ER? patients may assist in determining whether patients should have NAC or surgery as an initial treatment approach.
